Comparison of survival between unilateral and bilateral breast cancers using propensity score matching: a retrospective single-center analysis.

IF 3 3区医学 Q2 ONCOLOGY Breast Cancer Research and Treatment Pub Date : 2025-01-09 DOI:10.1007/s10549-024-07606-1

Talar Ozler, Rusen Cosar, Necdet Sut, Dilek Nurlu, Şule Parlar, Sinan Ateş, Mert Hacı Dertli, Yusuf Kavuzlu, Sekip Kavukcu, Mert Chousein, Gokay Yıldız, Nermin Tunçbilek, Muhammet Bekir Hacıoglu, Ebru Tastekin, Sernaz Topaloğlu

{"title":"Comparison of survival between unilateral and bilateral breast cancers using propensity score matching: a retrospective single-center analysis.","authors":"Talar Ozler, Rusen Cosar, Necdet Sut, Dilek Nurlu, Şule Parlar, Sinan Ateş, Mert Hacı Dertli, Yusuf Kavuzlu, Sekip Kavukcu, Mert Chousein, Gokay Yıldız, Nermin Tunçbilek, Muhammet Bekir Hacıoglu, Ebru Tastekin, Sernaz Topaloğlu","doi":"10.1007/s10549-024-07606-1","DOIUrl":null,"url":null,"abstract":"Purpose: The characteristics of patients with bilateral and unilateral breast cancer at the time of diagnosis or during follow-up have been compared, focusing on the differences in disease-free survival and overall survival between these groups.Methods: A total of 1,947 patients diagnosed with invasive carcinoma were included in the study. 1876 (96.4%) of our patients had unilateral and 71 (3.6%) had bilateral breast cancer. Among the bilateral breast cancer patients n = 47 were metachronous, while n = 24 were synchronous.Results: SBBC, which had the lowest OS duration, showed a statistically significant difference compared to MBCC, similar to that observed in unilateral breast cancer (p = 0.027).Conclusion: The fact that SBBC has the lowest survival rate despite more aggressive treatments should be considered a poor prognostic factor for survival on its own.","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Cancer Research and Treatment","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10549-024-07606-1","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: The characteristics of patients with bilateral and unilateral breast cancer at the time of diagnosis or during follow-up have been compared, focusing on the differences in disease-free survival and overall survival between these groups.

Methods: A total of 1,947 patients diagnosed with invasive carcinoma were included in the study. 1876 (96.4%) of our patients had unilateral and 71 (3.6%) had bilateral breast cancer. Among the bilateral breast cancer patients n = 47 were metachronous, while n = 24 were synchronous.

Results: SBBC, which had the lowest OS duration, showed a statistically significant difference compared to MBCC, similar to that observed in unilateral breast cancer (p = 0.027).

Conclusion: The fact that SBBC has the lowest survival rate despite more aggressive treatments should be considered a poor prognostic factor for survival on its own.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

使用倾向评分匹配比较单侧和双侧乳腺癌的生存率：回顾性单中心分析。

目的：比较双侧和单侧乳腺癌患者在诊断时和随访期间的特点，重点分析两组患者无病生存期和总生存期的差异。方法：共纳入1947例确诊为浸润性癌的患者。1876例（96.4%）为单侧乳腺癌，71例（3.6%）为双侧乳腺癌。双侧乳腺癌患者中，异时性47例，同步性24例。结果：SBBC与MBCC相比，OS持续时间最短，差异有统计学意义，与单侧乳腺癌相似（p = 0.027）。结论：尽管采取了更积极的治疗，但SBBC的生存率最低，这一事实本身应被视为预后不良的因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Breast Cancer Research and Treatment 医学-肿瘤学

CiteScore

6.80

自引率

2.60%

发文量

342

审稿时长

1 months

期刊介绍： Breast Cancer Research and Treatment provides the surgeon, radiotherapist, medical oncologist, endocrinologist, epidemiologist, immunologist or cell biologist investigating problems in breast cancer a single forum for communication. The journal creates a "market place" for breast cancer topics which cuts across all the usual lines of disciplines, providing a site for presenting pertinent investigations, and for discussing critical questions relevant to the entire field. It seeks to develop a new focus and new perspectives for all those concerned with breast cancer.